OOIR: Observatory of International Research

Papers

(The H4-Index of Translational Lung Cancer Research is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications	96
Radiomics and artificial intelligence in lung cancer screening	96
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival	71
Tumor-associated macrophages secret exosomal miR-155 and miR-196a-5p to promote metastasis of non-small-cell lung cancer	56
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma	51
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients	48
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer	47
Lung cancer screening and smoking cessation efforts	46
Transbronchial microwave ablation of lung nodules with electromagnetic navigation bronchoscopy guidance—a novel technique and initial experience with 30 cases	43
Current progress and mechanisms of bone metastasis in lung cancer: a narrative review	43
Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?	43
Emerging and multifaceted role of neutrophils in lung cancer	42
Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer	38
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis	38
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations	37
Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1	37
Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors	36
Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review	33
Lung cancer screening in Europe: where are we in 2021?	33
Expert consensus on resection of chest wall tumors and chest wall reconstruction	32
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma	32
tsRNA-5001a promotes proliferation of lung adenocarcinoma cells and is associated with postoperative recurrence in lung adenocarcinoma patients	32
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutati	32
Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review	31
Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2	30

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)	29
Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study	29
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups	28
CircP4HB regulates ferroptosis via SLC7A11-mediated glutathione synthesis in lung adenocarcinoma	28